What Can Investors Expect From Biocryst Pharmaceuticals (NASDAQ:BCRX) Shares After Seaport Global’s New Coverage?

June 23, 2018 - By Ash

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo

Investors sentiment decreased to 0.96 in Q1 2018. Its down 0.65, from 1.61 in 2017Q4. It is negative, as 20 investors sold BioCryst Pharmaceuticals, Inc. shares while 26 reduced holdings. 18 funds opened positions while 26 raised stakes. 85.89 million shares or 1.57% less from 87.26 million shares in 2017Q4 were reported.

State Bank Of Montreal Can stated it has 1,000 shares or 0% of all its holdings. Millennium Limited Company owns 2.69 million shares. Metropolitan Life Ny has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). California Public Employees Retirement reported 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Moreover, Sei Invests has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 588 shares. Goldman Sachs Group Inc holds 100,409 shares. D E Shaw accumulated 964,306 shares. Amalgamated Bank invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Northeast Financial Consultants holds 20,000 shares or 0.03% of its portfolio. Massachusetts-based Fmr Limited Liability Corporation has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). State Board Of Administration Of Florida Retirement Sys holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 54,434 shares. Swiss State Bank owns 171,300 shares. Moreover, Royal Bancshares Of Canada has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Pillar Pacific Lc has invested 0.01% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Washington-based Parametric Port Assoc Limited Liability Corp has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Since June 1, 2018, it had 0 insider buys, and 1 sale for $265,306 activity.

How Seaport Global Currently Rates Biocryst Pharmaceuticals (NASDAQ:BCRX)

Seaport Global has started coverage on Biocryst Pharmaceuticals (NASDAQ:BCRX) shares recently in analysts report revealed to investors and clients on 22 June. The financial firm has decided to place a “Neutral” rating on BCRX stock.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 3 analysts covering Biocryst Pharmaceuticals (NASDAQ:BCRX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Biocryst Pharmaceuticals has $10.0 highest and $1000 lowest target. $8’s average target is 43.11% above currents $5.59 stock price. Biocryst Pharmaceuticals had 4 analyst reports since January 2, 2018 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, January 2. H.C. Wainwright maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Tuesday, January 23. H.C. Wainwright has “Buy” rating and $10.0 target. The company was maintained on Wednesday, May 9 by H.C. Wainwright.

The stock decreased 3.12% or $0.18 during the last trading session, reaching $5.59. About 1.02 million shares traded or 28.89% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 9.66% since June 23, 2017 and is downtrending. It has underperformed by 22.23% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on August, 6. They expect $-0.21 earnings per share, 0.00 % or $0.00 from last year’s $-0.21 per share. After $-0.26 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23 % EPS growth.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $551.83 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

Another recent and important BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news was published by Nasdaq.com which published an article titled: “BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 …” on May 29, 2018.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: